Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
https://www.zacks.com/stock/news/2316389/regeneron-regn-q2-earnings-gain-from-eylea-hd-dupixent?cid=CS-ZC-FT-analyst_blog|earnings_article-2316389
Aug 05, 2024 - Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
0
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-abbv-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 05, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
https://www.zacks.com/stock/news/2310103/pharma-stock-roundup-azn-sny-abbv-q2-earnings-pfe-mrk-s-positive-pipeline-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2310103
Jul 26, 2024 - AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
0
Sanofi (SNY) Q2 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/07/25/sanofi-sny-q2-2024-earnings-call-transcript/?source=iedfolrf0000001
Jul 25, 2024 - SNY earnings call for the period ending June 30, 2024.
0
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
https://www.zacks.com/stock/news/2298585/kymera-s-kymr-partner-sny-to-expand-ongoing-hs-and-ad-studies?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2298585
Jul 09, 2024 - Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
0
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-lly-s-kisunla-sny-s-dupixent-gets-eu-nod-for-copd?cid=CS-ZC-FT-analyst_blog|stock_roundup-2297256
Jul 05, 2024 - Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
0
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
https://www.zacks.com/stock/news/2296528/regeneron-regn-sny-win-ec-approval-for-dupixent-for-copd?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296528
Jul 03, 2024 - Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
0
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
https://www.zacks.com/stock/news/2295861/regeneron-regn-gets-positive-chmp-opinion-for-lymphoma-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295861
Jul 01, 2024 - Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
0
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
https://www.zacks.com/stock/news/2293102/novavax-nvax-seeks-nod-for-updated-covid-19-jab-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293102
Jun 25, 2024 - Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
0
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
https://www.zacks.com/stock/news/2290253/abbvie-s-abbv-skyrizi-gets-fda-nod-for-ulcerative-colitis?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290253
Jun 19, 2024 - AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
0